This GLP-1 Stock Could Double by 2030. Here's Why

The article argues GLP-1 demand is accelerating, with the market potentially growing from ~$79B last year to ~$190B by 2035, which could be a tailwind for Viking Therapeutics. Viking’s lead candidate VK2735 is in phase 3 with potential approval targeted for mid-to-late 2028, alongside planned oral VK2735 late-stage trials and phase 1 work for VK3019 in Q2. The upside case is that VK2735 phase 3 results could drive “billions” in annual sales, but the stock is framed as high-risk because a phase 3 failure could cause a sharp drawdown from its ~$4.4B valuation.

Analysis

VKTX is not a “growth story” so much as a long-dated real option on clinical execution. The market’s mistake is usually to price obesity readouts as if efficacy alone wins; in practice, tolerability, dose titration, payer access, and manufacturing scale determine whether a small biotech can translate data into durable value. That means the stock can rerate violently on a clean readout, but the terminal valuation still depends on whether the drug is meaningfully better than the incumbents’ next-gen regimens rather than merely competitive.

The more interesting second-order effect is that a credible VKTX profile may expand the GLP-1 category instead of immediately displacing LLY/NVO. If oral use brings in treatment-naive patients, the near-term winners can still be the companies with the best distribution, reimbursement leverage, and supply chains, while VKTX absorbs the R&D and financing risk. Conversely, if the oral asset keeps showing discontinuation, the whole “mass market oral obesity” narrative gets compressed and the value of the program falls back to a niche adjunct story.

This is a binary setup over 12-18 months, with the market probably already assigning meaningful probability to success. The main falsifiers are phase 3 safety/efficacy misses, persistent oral tolerability problems, or a broader slowdown in GLP-1 demand that makes the addressable market smaller than consensus assumes. Also watch financing: a clinical-stage company with a multi-year path to commercialization can still get diluted even after a good data point if it has to keep funding late-stage and launch preparations.

Key Decisions for Investors

• Do not chase VKTX common stock into strength; wait for a 10-15% pullback or the next clinical inflection. Risk/reward is acceptable only if you are buying before a data catalyst with clearly defined downside.
• For tactical exposure to the obesity theme, use a call spread in VKTX rather than outright equity into phase 3 completion over the next 12-18 months. This preserves upside if data are strong while capping the binary downside from a miss.
• If you want lower-beta GLP-1 exposure, prefer LLY or NVO on any VKTX-driven weakness. The market may overestimate how quickly a new entrant can convert data into share; incumbents still control reimbursement and supply.
• Avoid shorting LLY/NVO solely on the VKTX story. The more likely 6-18 month outcome is category expansion and incremental patient capture, not immediate displacement of the leaders.
• Set a watch item on VKTX oral discontinuation/titration updates and phase 3 safety readouts; if tolerability improves, the thesis becomes much more durable. If not, treat any rally as a financing-risk-driven squeeze rather than a fundamental rerating.